25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

BPMC (Blueprint Medicines Corp) Stock Analysis
Buy, Hold or Sell?

Let's analyze Blueprint Medicines Corp together

I guess you are interested in Blueprint Medicines Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Blueprint Medicines Corp’s Financial Insights
  • 📈 Technical Analysis (TA) – Blueprint Medicines Corp’s Price Targets

I'm going to help you getting a better view of Blueprint Medicines Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Blueprint Medicines Corp

I send you an email if I find something interesting about Blueprint Medicines Corp.

1. Quick Overview

1.1. Quick analysis of Blueprint Medicines Corp (30 sec.)










1.2. What can you expect buying and holding a share of Blueprint Medicines Corp? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
12.5%

What is your share worth?

Current worth
$5.30
Expected worth in 1 year
$5.78
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$0.49
Return On Investment
0.4%

For what price can you sell your share?

Current Price per Share
$128.35
Expected price per share
$104.86 - $128.45
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Blueprint Medicines Corp (5 min.)




Live pricePrice per Share (EOD)
$128.35
Intrinsic Value Per Share
$-55.32 - $39.66
Total Value Per Share
$-50.02 - $44.96

2.2. Growth of Blueprint Medicines Corp (5 min.)




Is Blueprint Medicines Corp growing?

Current yearPrevious yearGrowGrow %
How rich?$342.1m$238.7m$79.7m25.0%

How much money is Blueprint Medicines Corp making?

Current yearPrevious yearGrowGrow %
Making money-$38.9m-$72m$33.1m85.1%
Net Profit Margin-28.5%-132.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Blueprint Medicines Corp (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#176 / 881

Most Revenue
#70 / 881

Most Profit
#749 / 881

Most Efficient
#454 / 881
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Blueprint Medicines Corp?

Welcome investor! Blueprint Medicines Corp's management wants to use your money to grow the business. In return you get a share of Blueprint Medicines Corp.

First you should know what it really means to hold a share of Blueprint Medicines Corp. And how you can make/lose money.

Speculation

The Price per Share of Blueprint Medicines Corp is $128.35. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Blueprint Medicines Corp.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Blueprint Medicines Corp, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.30. Based on the TTM, the Book Value Change Per Share is $0.12 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.40 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Blueprint Medicines Corp.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.010.0%-0.60-0.5%-1.12-0.9%-1.32-1.0%-1.05-0.8%-0.89-0.7%
Usd Book Value Change Per Share0.670.5%0.120.1%-0.40-0.3%-0.70-0.5%-0.26-0.2%0.120.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.070.1%
Usd Total Gains Per Share0.670.5%0.120.1%-0.40-0.3%-0.70-0.5%-0.26-0.2%0.190.1%
Usd Price Per Share88.51-94.00-75.13-73.48-81.18-67.58-
Price to Earnings Ratio2,881.13-697.90--2.50-229.87-133.57-55.87-
Price-to-Total Gains Ratio131.51--92.77--29.54--50.39--45.99--54.11-
Price to Book Ratio16.71-19.10-23.61-16.20-11.92-11.22-
Price-to-Total Gains Ratio131.51--92.77--29.54--50.39--45.99--54.11-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share128.35
Number of shares7
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.12-0.26
Usd Total Gains Per Share0.12-0.26
Gains per Quarter (7 shares)0.85-1.85
Gains per Year (7 shares)3.41-7.39
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
103-70-7-17
207-40-15-24
3010-10-22-31
401420-30-38
501750-37-45
602080-44-52
7024110-52-59
8027140-59-66
9031170-66-73
10034200-74-80

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%3.037.00.07.5%3.042.01.06.5%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%5.015.00.025.0%11.029.00.027.5%12.031.03.026.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%5.00.035.012.5%5.00.041.010.9%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%5.015.00.025.0%12.028.00.030.0%13.030.03.028.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Blueprint Medicines Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.6730.122+453%-0.401+160%-0.696+203%-0.264+139%0.123+448%
Book Value Per Share--5.2984.932+7%3.697+43%5.866-10%10.642-50%8.102-35%
Current Ratio--2.8023.168-12%4.104-32%4.417-37%5.113-45%7.261-61%
Debt To Asset Ratio--0.7140.733-3%0.778-8%0.688+4%0.487+46%0.368+94%
Debt To Equity Ratio--2.4952.759-10%4.097-39%2.739-9%1.737+44%1.044+139%
Dividend Per Share----0%-0%-0%-0%0.065-100%
Enterprise Value--5438934522.0005867152755.500-7%4771536186.000+14%4744400350.500+15%5482112472.700-1%4627723086.600+18%
Eps--0.008-0.603+7949%-1.116+14631%-1.323+17323%-1.045+13712%-0.894+11735%
Ev To Ebitda Ratio---33.095-46.053+39%-12.534-62%-21.847-34%-18.016-46%-21.178-36%
Ev To Sales Ratio--9.10110.500-13%16.901-46%15.329-41%32.844-72%223.369-96%
Free Cash Flow Per Share---0.872-0.584-33%-1.664+91%-1.398+60%-0.993+14%-0.804-8%
Free Cash Flow To Equity Per Share---0.7300.249-393%-0.944+29%-0.150-79%0.034-2234%0.285-356%
Gross Profit Margin--1.0001.384-28%1.050-5%1.165-14%1.105-10%1.054-5%
Intrinsic Value_10Y_max--39.658----------
Intrinsic Value_10Y_min---55.320----------
Intrinsic Value_1Y_max---2.178----------
Intrinsic Value_1Y_min---5.621----------
Intrinsic Value_3Y_max---1.856----------
Intrinsic Value_3Y_min---16.922----------
Intrinsic Value_5Y_max--4.119----------
Intrinsic Value_5Y_min---28.172----------
Market Cap8289125370.000+31%5716170522.0006070888255.500-6%4852060686.000+18%4745338600.500+20%5242686122.700+9%4364335911.600+31%
Net Profit Margin--0.003-0.285+8677%-1.321+39897%-1.579+47669%-2.676+80710%-12.351+372141%
Operating Margin---0.046-0.197+330%-1.627+3452%-1.600+3392%-2.704+5803%-12.530+27254%
Operating Ratio--1.2751.313-3%2.696-53%2.671-52%3.741-66%23.115-94%
Pb Ratio24.228+31%16.70819.095-13%23.614-29%16.196+3%11.919+40%11.219+49%
Pe Ratio4177.987+31%2881.134697.900+313%-2.498+100%229.871+1153%133.566+2057%55.872+5057%
Price Per Share128.350+31%88.51094.003-6%75.130+18%73.478+20%81.179+9%67.578+31%
Price To Free Cash Flow Ratio-36.801-45%-25.378-53.884+112%-11.933-53%-24.127-5%-21.821-14%-25.173-1%
Price To Total Gains Ratio190.704+31%131.509-92.769+171%-29.541+122%-50.389+138%-45.995+135%-54.107+141%
Quick Ratio--4.4305.263-16%7.307-39%7.638-42%8.159-46%11.386-61%
Return On Assets--0.000-0.033+7957%-0.065+15821%-0.070+16977%-0.060+14457%-0.078+18927%
Return On Equity--0.001-0.125+8751%-0.412+28538%-0.266+18455%-0.184+12788%-0.158+11013%
Total Gains Per Share--0.6730.122+453%-0.401+160%-0.696+203%-0.264+139%0.188+258%
Usd Book Value--342131000.000318546250.000+7%238759250.000+43%378854500.000-10%687301100.000-50%523276150.000-35%
Usd Book Value Change Per Share--0.6730.122+453%-0.401+160%-0.696+203%-0.264+139%0.123+448%
Usd Book Value Per Share--5.2984.932+7%3.697+43%5.866-10%10.642-50%8.102-35%
Usd Dividend Per Share----0%-0%-0%-0%0.065-100%
Usd Enterprise Value--5438934522.0005867152755.500-7%4771536186.000+14%4744400350.500+15%5482112472.700-1%4627723086.600+18%
Usd Eps--0.008-0.603+7949%-1.116+14631%-1.323+17323%-1.045+13712%-0.894+11735%
Usd Free Cash Flow---56310000.000-37727250.000-33%-107495250.000+91%-90312666.667+60%-64139800.000+14%-51925925.000-8%
Usd Free Cash Flow Per Share---0.872-0.584-33%-1.664+91%-1.398+60%-0.993+14%-0.804-8%
Usd Free Cash Flow To Equity Per Share---0.7300.249-393%-0.944+29%-0.150-79%0.034-2234%0.285-356%
Usd Market Cap8289125370.000+31%5716170522.0006070888255.500-6%4852060686.000+18%4745338600.500+20%5242686122.700+9%4364335911.600+31%
Usd Price Per Share128.350+31%88.51094.003-6%75.130+18%73.478+20%81.179+9%67.578+31%
Usd Profit--496000.000-38932500.000+7949%-72072000.000+14631%-85424083.333+17323%-67516950.000+13712%-57686025.000+11730%
Usd Revenue--149413000.000140530000.000+6%70552250.000+112%87410083.333+71%103965050.000+44%56411175.000+165%
Usd Total Gains Per Share--0.6730.122+453%-0.401+160%-0.696+203%-0.264+139%0.188+258%
 EOD+5 -3MRQTTM+22 -16YOY+31 -73Y+24 -145Y+21 -1710Y+20 -20

3.3 Fundamental Score

Let's check the fundamental score of Blueprint Medicines Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-154,177.987
Price to Book Ratio (EOD)Between0-124.228
Net Profit Margin (MRQ)Greater than00.003
Operating Margin (MRQ)Greater than0-0.046
Quick Ratio (MRQ)Greater than14.430
Current Ratio (MRQ)Greater than12.802
Debt to Asset Ratio (MRQ)Less than10.714
Debt to Equity Ratio (MRQ)Less than12.495
Return on Equity (MRQ)Greater than0.150.001
Return on Assets (MRQ)Greater than0.050.000
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Blueprint Medicines Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5074.588
Ma 20Greater thanMa 50128.143
Ma 50Greater thanMa 100111.575
Ma 100Greater thanMa 200100.425
OpenGreater thanClose128.250
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2025-06-19 01:26:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Blueprint Medicines Corp earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Blueprint Medicines Corp to the Biotechnology industry mean.
  • A Net Profit Margin of 0.3% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Blueprint Medicines Corp:

  • The MRQ is 0.3%. The company is not making a profit/loss.
  • The TTM is -28.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ0.3%TTM-28.5%+28.8%
TTM-28.5%YOY-132.1%+103.6%
TTM-28.5%5Y-267.6%+239.1%
5Y-267.6%10Y-1,235.1%+967.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3%-91.7%+92.0%
TTM-28.5%-139.0%+110.5%
YOY-132.1%-194.4%+62.3%
3Y-157.9%-248.5%+90.6%
5Y-267.6%-343.3%+75.7%
10Y-1,235.1%-488.9%-746.2%
4.3.1.2. Return on Assets

Shows how efficient Blueprint Medicines Corp is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Blueprint Medicines Corp to the Biotechnology industry mean.
  • 0.0% Return on Assets means that Blueprint Medicines Corp generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Blueprint Medicines Corp:

  • The MRQ is 0.0%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -3.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.0%TTM-3.3%+3.3%
TTM-3.3%YOY-6.5%+3.3%
TTM-3.3%5Y-6.0%+2.7%
5Y-6.0%10Y-7.8%+1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0%-11.6%+11.6%
TTM-3.3%-11.7%+8.4%
YOY-6.5%-11.4%+4.9%
3Y-7.0%-11.9%+4.9%
5Y-6.0%-12.1%+6.1%
10Y-7.8%-13.8%+6.0%
4.3.1.3. Return on Equity

Shows how efficient Blueprint Medicines Corp is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Blueprint Medicines Corp to the Biotechnology industry mean.
  • 0.1% Return on Equity means Blueprint Medicines Corp generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Blueprint Medicines Corp:

  • The MRQ is 0.1%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -12.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.1%TTM-12.5%+12.7%
TTM-12.5%YOY-41.2%+28.7%
TTM-12.5%5Y-18.4%+5.9%
5Y-18.4%10Y-15.8%-2.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1%-13.5%+13.6%
TTM-12.5%-15.0%+2.5%
YOY-41.2%-14.5%-26.7%
3Y-26.6%-16.9%-9.7%
5Y-18.4%-17.9%-0.5%
10Y-15.8%-19.9%+4.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Blueprint Medicines Corp.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Blueprint Medicines Corp is operating .

  • Measures how much profit Blueprint Medicines Corp makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Blueprint Medicines Corp to the Biotechnology industry mean.
  • An Operating Margin of -4.6% means the company generated $-0.05  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Blueprint Medicines Corp:

  • The MRQ is -4.6%. The company is operating very inefficient. -2
  • The TTM is -19.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-4.6%TTM-19.7%+15.1%
TTM-19.7%YOY-162.7%+143.0%
TTM-19.7%5Y-270.4%+250.7%
5Y-270.4%10Y-1,253.0%+982.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.6%-229.2%+224.6%
TTM-19.7%-249.7%+230.0%
YOY-162.7%-208.4%+45.7%
3Y-160.0%-221.7%+61.7%
5Y-270.4%-344.1%+73.7%
10Y-1,253.0%-470.4%-782.6%
4.3.2.2. Operating Ratio

Measures how efficient Blueprint Medicines Corp is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.27 means that the operating costs are $1.27 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Blueprint Medicines Corp:

  • The MRQ is 1.275. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.313. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.275TTM1.313-0.038
TTM1.313YOY2.696-1.383
TTM1.3135Y3.741-2.428
5Y3.74110Y23.115-19.374
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2752.108-0.833
TTM1.3132.680-1.367
YOY2.6963.080-0.384
3Y2.6713.621-0.950
5Y3.7414.734-0.993
10Y23.1156.546+16.569
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Blueprint Medicines Corp.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Blueprint Medicines Corp is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.80 means the company has $2.80 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Blueprint Medicines Corp:

  • The MRQ is 2.802. The company is able to pay all its short-term debts. +1
  • The TTM is 3.168. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.802TTM3.168-0.367
TTM3.168YOY4.104-0.935
TTM3.1685Y5.113-1.945
5Y5.11310Y7.261-2.148
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8023.659-0.857
TTM3.1683.834-0.666
YOY4.1044.141-0.037
3Y4.4174.661-0.244
5Y5.1135.756-0.643
10Y7.2616.151+1.110
4.4.3.2. Quick Ratio

Measures if Blueprint Medicines Corp is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Blueprint Medicines Corp to the Biotechnology industry mean.
  • A Quick Ratio of 4.43 means the company can pay off $4.43 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Blueprint Medicines Corp:

  • The MRQ is 4.430. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.263. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.430TTM5.263-0.833
TTM5.263YOY7.307-2.044
TTM5.2635Y8.159-2.896
5Y8.15910Y11.386-3.227
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.4302.799+1.631
TTM5.2633.143+2.120
YOY7.3073.794+3.513
3Y7.6384.307+3.331
5Y8.1595.707+2.452
10Y11.3866.457+4.929
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Blueprint Medicines Corp.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Blueprint Medicines Corp assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Blueprint Medicines Corp to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.71 means that Blueprint Medicines Corp assets are financed with 71.4% credit (debt) and the remaining percentage (100% - 71.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Blueprint Medicines Corp:

  • The MRQ is 0.714. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.733. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.714TTM0.733-0.020
TTM0.733YOY0.778-0.045
TTM0.7335Y0.487+0.246
5Y0.48710Y0.368+0.119
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7140.324+0.390
TTM0.7330.347+0.386
YOY0.7780.329+0.449
3Y0.6880.340+0.348
5Y0.4870.349+0.138
10Y0.3680.379-0.011
4.5.4.2. Debt to Equity Ratio

Measures if Blueprint Medicines Corp is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Blueprint Medicines Corp to the Biotechnology industry mean.
  • A Debt to Equity ratio of 249.5% means that company has $2.49 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Blueprint Medicines Corp:

  • The MRQ is 2.495. The company is just not able to pay all its debts with equity.
  • The TTM is 2.759. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.495TTM2.759-0.264
TTM2.759YOY4.097-1.338
TTM2.7595Y1.737+1.022
5Y1.73710Y1.044+0.693
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4950.379+2.116
TTM2.7590.435+2.324
YOY4.0970.412+3.685
3Y2.7390.446+2.293
5Y1.7370.460+1.277
10Y1.0440.509+0.535
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Blueprint Medicines Corp generates.

  • Above 15 is considered overpriced but always compare Blueprint Medicines Corp to the Biotechnology industry mean.
  • A PE ratio of 2,881.13 means the investor is paying $2,881.13 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Blueprint Medicines Corp:

  • The EOD is 4,177.987. Based on the earnings, the company is expensive. -2
  • The MRQ is 2,881.134. Based on the earnings, the company is expensive. -2
  • The TTM is 697.900. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD4,177.987MRQ2,881.134+1,296.852
MRQ2,881.134TTM697.900+2,183.234
TTM697.900YOY-2.498+700.398
TTM697.9005Y133.566+564.334
5Y133.56610Y55.872+77.694
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4,177.987-2.282+4,180.269
MRQ2,881.134-2.062+2,883.196
TTM697.900-2.541+700.441
YOY-2.498-3.722+1.224
3Y229.871-3.754+233.625
5Y133.566-6.100+139.666
10Y55.872-6.653+62.525
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Blueprint Medicines Corp:

  • The EOD is -36.801. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -25.378. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -53.884. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-36.801MRQ-25.378-11.423
MRQ-25.378TTM-53.884+28.506
TTM-53.884YOY-11.933-41.952
TTM-53.8845Y-21.821-32.063
5Y-21.82110Y-25.173+3.352
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-36.801-3.101-33.700
MRQ-25.378-2.689-22.689
TTM-53.884-3.594-50.290
YOY-11.933-4.363-7.570
3Y-24.127-5.065-19.062
5Y-21.821-8.478-13.343
10Y-25.173-9.273-15.900
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Blueprint Medicines Corp is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 16.71 means the investor is paying $16.71 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Blueprint Medicines Corp:

  • The EOD is 24.228. Based on the equity, the company is expensive. -2
  • The MRQ is 16.708. Based on the equity, the company is expensive. -2
  • The TTM is 19.095. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD24.228MRQ16.708+7.520
MRQ16.708TTM19.095-2.387
TTM19.095YOY23.614-4.519
TTM19.0955Y11.919+7.177
5Y11.91910Y11.219+0.700
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD24.2281.932+22.296
MRQ16.7081.848+14.860
TTM19.0952.119+16.976
YOY23.6142.469+21.145
3Y16.1962.526+13.670
5Y11.9193.667+8.252
10Y11.2194.351+6.868
4.6.2. Total Gains per Share

2.4. Latest News of Blueprint Medicines Corp

Does Blueprint Medicines Corp still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Blueprint Medicines Corp to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-07-01
19:23
Blueprint Medicines stock hits all-time high at 128.45 USDRead
2025-06-23
21:11
Blueprint Medicines stock hits all-time high at 128.34 USDRead
2025-06-23
19:38
Exploring 3 High Growth Tech Stocks In The US MarketRead
2025-06-21
19:01
BPMC Quantitative Stock AnalysisRead
2025-06-19
19:38
Exploring Three High Growth Tech Stocks In The US MarketRead
2025-06-14
19:33
Blueprint Medicines' SWOT analysis: stock poised for growth amid Sanofi acquisitionRead
2025-06-08
15:05
Notable healthcare headlines for the week: Bristol Myers Squibb, Novo Nordisk and Sanofi in focusRead
2025-06-07
21:05
BPMC Quantitative Stock AnalysisRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Blueprint Medicines Corp.

4.8.1. Institutions holding Blueprint Medicines Corp

Institutions are holding 109.404% of the shares of Blueprint Medicines Corp.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31BlackRock Inc10.37750.01256710708-158619-2.3091
2025-03-31Vanguard Group Inc10.26890.01066640523-134361-1.9832
2025-03-31T. Rowe Price Associates, Inc.8.37510.05915415837-263252-4.6355
2025-03-31venBio Select Advisor LLC5.95375.31938500002665000224.8945
2025-03-31Wellington Management Company LLP4.75260.05233073306-1208058-28.2167
2025-03-31State Street Corp4.15070.009826841171839107.3558
2025-03-31JPMorgan Chase & Co3.87610.016225065141350880116.8951
2025-03-31Geode Capital Management, LLC2.35460.01061522647325462.1841
2025-03-31FMR Inc2.21630.00811433169-814510-36.2378
2025-03-31William Blair Investment Management, LLC2.21080.35521429668-515027-26.4837
2025-03-31T. Rowe Price Investment Management,Inc.2.01470.0763130281060578386.9095
2025-03-31Macquarie Group Ltd1.99010.14881286897279212.2178
2024-12-31AllianceBernstein L.P.1.75980.03371138022-79683-6.5437
2025-03-31Rock Springs Capital Management LP1.55815.10241007569-89330-8.1439
2025-03-31Amvescap Plc.1.52270.0165984674242372.5235
2025-03-31Pictet Asset Manangement SA1.47620.0939954596-229086-19.3537
2025-03-31Goldman Sachs Group Inc1.4330.0133926668-119867-11.4537
2025-03-31Alkeon Capital Management, LLC1.39270.166190062810000012.4902
2025-03-31Hood River Capital Management LLC1.39211.3594900205202732.3039
2025-03-31American Century Companies Inc1.34040.0471866763275603.2841
Total 70.416112.910945535321+1426317+3.1%

4.9.2. Funds holding Blueprint Medicines Corp

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Total Stock Mkt Idx Inv3.16410.01072046098363081.8066
2025-03-31US Small-Cap Growth II Equity Comp3.08861.09771997279-54297-2.6466
2025-03-31T. Rowe Price New Horizons3.08861.09771997279-27009-1.3342
2025-04-30Vanguard Small Cap Index2.48090.1023160427489920.5637
2025-05-31iShares Russell 2000 ETF2.46310.2622159277400
2025-03-31T. Rowe Price Health Sciences2.38011.10491539139-80021-4.9421
2025-03-31Vanguard Health Care Inv2.10770.30971362970-727094-34.7881
2025-05-31SPDR® S&P Biotech ETF1.76732.4687114286067620.5952
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.52640.086798707258330.5945
2025-04-30Macquarie Small Cap Core I1.41131.2234912639-22096-2.3639
2025-04-30Vanguard Small Cap Growth Index Inv1.38130.2394893251-1274-0.1424
2025-04-30JPMorgan Growth Advantage A1.19850.361177504737168492.1463
2025-03-31Vanguard Explorer Inv1.11950.3228723936-79419-9.8859
2025-03-31Fidelity Small Cap Index0.98170.232463482945700.7251
2025-03-31T. Rowe Price New Horizons Tr-A0.88271.1194570839413867.8167
2025-05-31iShares Russell 2000 Growth ETF0.85280.505955148000
2025-03-31Hood River Small-Cap Growth Instl0.78651.354550858900
2025-04-30JPMorgan Small Cap Growth A0.72351.385446783000
2025-04-30Polar Capital Biotech S Inc0.69592.2488450000-50000-10
2025-03-31JPM US Growth Advantage-MA0.69230.36294477014477010
Total 32.792815.896621205886-117974-0.6%

5.3. Insider Transactions

Insiders are holding 0.863% of the shares of Blueprint Medicines Corp.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-05-27Jeffrey W AlbersSELL5000101.14
2025-05-19Christina RossiSELL2274100.51
2025-05-05Ariel HurleySELL2752103.13
2025-05-05Christina RossiSELL2274101.75
2025-03-24Christina RossiSELL227495.02
2025-03-03Ariel HurleySELL320392.62
2025-01-21Christina RossiSELL2274110.14
2025-01-21Jeffrey W AlbersSELL15161109.53
2025-01-21Kate HavilandSELL1446110.24
2025-01-13Ariel HurleySELL2250100
2025-01-13Jeffrey W AlbersSELL5000102.28
2024-12-19Jeffrey W AlbersSELL1500089.77
2024-12-18Christina RossiSELL227495.91
2024-12-12Ariel HurleySELL181993.26
2024-11-29Kate HavilandSELL235396.6
2024-11-27Christina RossiSELL227495.1
2024-10-03Fouad NamouniSELL363389.32
2024-08-05Philina LeeSELL4191393.19
2024-07-05Debra Durso-bumpusSELL3850111.2
2024-07-03Debra Durso-bumpusSELL8817111.29
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Depreciation and Amortization  4,810-1,1933,6172463,8631384,001-38,243-34,242



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,195,604
Total Liabilities853,473
Total Stockholder Equity342,131
 As reported
Total Liabilities 853,473
Total Stockholder Equity+ 342,131
Total Assets = 1,195,604

Assets

Total Assets1,195,604
Total Current Assets702,069
Long-term Assets493,535
Total Current Assets
Cash And Cash Equivalents 122,245
Short-term Investments 453,992
Net Receivables 79,801
Inventory 12,953
Other Current Assets 33,078
Total Current Assets  (as reported)702,069
Total Current Assets  (calculated)702,069
+/-0
Long-term Assets
Property Plant Equipment 97,657
Long Term Investments 323,547
Long-term Assets  (as reported)493,535
Long-term Assets  (calculated)421,204
+/- 72,331

Liabilities & Shareholders' Equity

Total Current Liabilities250,584
Long-term Liabilities602,889
Total Stockholder Equity342,131
Total Current Liabilities
Short-term Debt 57,533
Short Long Term Debt 43,797
Accounts payable 800
Other Current Liabilities 189,972
Total Current Liabilities  (as reported)250,584
Total Current Liabilities  (calculated)292,102
+/- 41,518
Long-term Liabilities
Long term Debt 343,949
Capital Lease Obligations 78,952
Long-term Liabilities Other 6,972
Long-term Liabilities  (as reported)602,889
Long-term Liabilities  (calculated)429,873
+/- 173,016
Total Stockholder Equity
Common Stock65
Retained Earnings -2,406,535
Accumulated Other Comprehensive Income -3,237
Other Stockholders Equity 2,751,838
Total Stockholder Equity (as reported)342,131
Total Stockholder Equity (calculated)342,131
+/-0
Other
Capital Stock65
Cash and Short Term Investments 576,237
Common Stock Shares Outstanding 63,600
Current Deferred Revenue2,279
Liabilities and Stockholders Equity 1,195,604
Net Debt 504
Net Invested Capital 729,877
Net Working Capital 451,485
Property Plant and Equipment Gross 97,657
Short Long Term Debt Total 122,749



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-31
> Total Assets 
4,135
0
0
0
49,925
55,910
204,208
195,288
178,898
206,010
186,520
167,849
282,795
252,648
444,721
420,118
715,737
664,468
665,113
606,110
540,124
544,663
807,178
737,925
707,694
913,623
817,457
1,558,178
1,718,393
1,625,387
1,568,795
1,477,322
1,252,225
1,143,307
1,192,446
1,458,392
1,349,902
1,220,370
1,106,445
1,105,299
1,049,250
1,038,475
1,203,560
1,199,649
1,179,813
1,195,604
1,195,6041,179,8131,199,6491,203,5601,038,4751,049,2501,105,2991,106,4451,220,3701,349,9021,458,3921,192,4461,143,3071,252,2251,477,3221,568,7951,625,3871,718,3931,558,178817,457913,623707,694737,925807,178544,663540,124606,110665,113664,468715,737420,118444,721252,648282,795167,849186,520206,010178,898195,288204,20855,91049,9250004,135
   > Total Current Assets 
0
1,987
0
0
48,274
52,180
201,443
188,587
170,416
197,667
178,120
159,448
220,425
213,958
431,328
400,279
685,505
615,698
622,213
565,657
499,787
426,516
612,952
513,726
516,786
704,683
568,312
841,655
927,759
937,710
704,070
771,848
554,025
687,244
952,179
1,227,665
1,046,651
900,344
811,335
808,172
808,393
776,602
903,544
854,848
742,678
702,069
702,069742,678854,848903,544776,602808,393808,172811,335900,3441,046,6511,227,665952,179687,244554,025771,848704,070937,710927,759841,655568,312704,683516,786513,726612,952426,516499,787565,657622,213615,698685,505400,279431,328213,958220,425159,448178,120197,667170,416188,587201,44352,18048,274001,9870
       Cash And Cash Equivalents 
1,987
-1,987
0
0
47,240
50,298
193,587
179,780
162,707
122,289
109,386
74,403
268,218
56,356
91,346
57,329
673,356
134,886
117,751
78,641
68,064
79,391
82,425
89,237
113,938
375,168
288,678
565,221
684,636
697,966
534,317
553,593
209,948
37,199
173,399
291,430
119,709
169,724
75,527
55,972
71,286
113,326
54,771
89,356
102,014
122,245
122,245102,01489,35654,771113,32671,28655,97275,527169,724119,709291,430173,39937,199209,948553,593534,317697,966684,636565,221288,678375,168113,93889,23782,42579,39168,06478,641117,751134,886673,35657,32991,34656,356268,21874,403109,386122,289162,707179,780193,58750,29847,24000-1,9871,987
       Short-term Investments 
0
3,974
0
0
119
119
119
119
119
69,218
63,167
78,141
162,090
150,040
329,668
333,323
273,052
472,439
495,705
480,995
425,948
336,465
510,436
404,205
369,616
291,596
233,120
192,209
187,213
153,995
94,032
148,285
267,166
549,627
679,712
845,535
825,283
652,437
647,107
657,012
639,355
534,575
708,831
644,817
513,473
453,992
453,992513,473644,817708,831534,575639,355657,012647,107652,437825,283845,535679,712549,627267,166148,28594,032153,995187,213192,209233,120291,596369,616404,205510,436336,465425,948480,995495,705472,439273,052333,323329,668150,040162,09078,14163,16769,218119119119119119003,9740
       Net Receivables 
0
0
0
0
3,414
484
1,923
2,470
3,414
4,232
3,351
3,455
3,577
2,826
3,075
3,435
0
0
0
0
215
0
5,264
5,076
23,412
25,107
24,280
61,256
25,309
43,863
39,240
29,724
37,030
32,598
29,410
21,915
36,938
31,303
38,267
41,254
43,178
60,047
85,058
65,814
77,609
79,801
79,80177,60965,81485,05860,04743,17841,25438,26731,30336,93821,91529,41032,59837,03029,72439,24043,86325,30961,25624,28025,10723,4125,0765,264021500003,4353,0752,8263,5773,4553,3514,2323,4142,4701,9234843,4140000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
-54,059
0
0
0
0
0
0
0
0
0
0
0
-64,406
2,665
4,359
5,565
8,581
16,030
15,211
16,570
21,817
30,145
35,454
35,253
29,697
17,521
17,016
16,457
21,223
30,940
14,789
12,528
13,611
12,953
12,95313,61112,52814,78930,94021,22316,45717,01617,52129,69735,25335,45430,14521,81716,57015,21116,0308,5815,5654,3592,665-64,40600000000000-54,059000000000000
   > Long-term Assets 
0
-1,987
0
0
1,651
3,730
2,765
6,701
8,482
8,343
8,400
8,401
62,370
38,690
13,393
19,839
30,232
48,770
42,900
40,453
40,337
118,147
194,226
224,199
190,908
208,940
249,145
716,523
790,634
687,677
864,725
705,474
698,200
456,063
240,267
230,727
303,251
320,026
295,110
297,127
240,857
261,873
300,016
344,801
437,135
493,535
493,535437,135344,801300,016261,873240,857297,127295,110320,026303,251230,727240,267456,063698,200705,474864,725687,677790,634716,523249,145208,940190,908224,199194,226118,14740,33740,45342,90048,77030,23219,83913,39338,69062,3708,4018,4008,3438,4826,7012,7653,7301,65100-1,9870
       Property Plant Equipment 
1,404
0
0
0
1,482
1,295
1,393
4,805
6,661
6,537
6,565
6,578
6,188
6,081
7,774
13,416
24,363
29,074
30,250
29,720
29,627
107,143
108,780
112,277
111,114
109,725
107,216
104,219
101,668
98,978
96,294
94,190
120,862
119,229
119,020
117,371
115,198
113,409
114,486
115,840
115,650
113,169
109,048
104,266
100,774
97,657
97,657100,774104,266109,048113,169115,650115,840114,486113,409115,198117,371119,020119,229120,86294,19096,29498,978101,668104,219107,216109,725111,114112,277108,780107,14329,62729,72030,25029,07424,36313,4167,7746,0816,1886,5786,5656,5376,6614,8051,3931,2951,4820001,404
       Long Term Investments 
0
0
0
0
54,059
0
0
0
0
0
0
0
54,059
29,929
0
0
0
13,798
3,195
0
0
0
74,398
101,017
64,406
83,666
128,475
598,470
677,873
578,168
751,702
591,920
557,529
306,525
94,048
55,675
133,480
139,150
113,932
142,031
84,319
115,492
132,658
176,879
277,149
323,547
323,547277,149176,879132,658115,49284,319142,031113,932139,150133,48055,67594,048306,525557,529591,920751,702578,168677,873598,470128,47583,66664,406101,01774,3980003,19513,79800029,92954,059000000054,0590000
       Long-term Assets Other 
0
-1,987
0
0
169
2,435
1,372
1,896
1,821
1,806
1,835
1,823
2,123
2,680
5,619
6,423
5,869
5,898
9,455
10,733
10,710
11,004
11,048
10,905
15,388
15,549
13,454
13,834
11,093
10,531
16,729
19,364
19,809
30,309
27,199
29,892
26,784
39,678
38,903
39,256
30,650
22,578
47,687
240,535
59,212
395,878
395,87859,212240,53547,68722,57830,65039,25638,90339,67826,78429,89227,19930,30919,80919,36416,72910,53111,09313,83413,45415,54915,38810,90511,04811,00410,71010,7339,4555,8985,8696,4235,6192,6802,1231,8231,8351,8061,8211,8961,3722,43516900-1,9870
> Total Liabilities 
5,631
0
0
0
14,496
31,187
34,619
37,146
34,919
76,351
73,958
70,139
69,717
64,426
70,632
78,878
91,767
93,595
112,181
116,814
121,115
200,450
214,351
221,581
243,335
230,692
236,090
238,178
248,305
225,366
239,991
230,235
281,490
261,641
444,696
818,085
835,225
806,072
795,315
902,688
918,641
727,788
883,319
886,501
881,148
853,473
853,473881,148886,501883,319727,788918,641902,688795,315806,072835,225818,085444,696261,641281,490230,235239,991225,366248,305238,178236,090230,692243,335221,581214,351200,450121,115116,814112,18193,59591,76778,87870,63264,42669,71770,13973,95876,35134,91937,14634,61931,18714,4960005,631
   > Total Current Liabilities 
3,153
0
0
0
6,764
14,630
14,451
19,291
18,640
23,782
27,754
24,380
28,512
25,759
32,992
35,490
42,890
39,998
50,333
56,279
60,323
64,763
81,506
94,142
106,482
98,288
105,086
110,108
130,802
112,437
125,397
119,691
149,765
137,025
158,760
175,510
183,234
172,684
169,028
197,384
214,923
206,603
243,803
257,661
260,796
250,584
250,584260,796257,661243,803206,603214,923197,384169,028172,684183,234175,510158,760137,025149,765119,691125,397112,437130,802110,108105,08698,288106,48294,14281,50664,76360,32356,27950,33339,99842,89035,49032,99225,75928,51224,38027,75423,78218,64019,29114,45114,6306,7640003,153
       Short-term Debt 
0
0
0
0
1,704
2,127
3,708
4,134
3,844
4,428
4,189
3,370
3,129
2,718
3,693
3,532
3,232
2,820
2,406
1,991
1,714
10,556
12,714
13,174
6,823
14,338
14,832
15,344
7,935
16,386
16,930
17,620
8,093
17,524
9,435
25,406
27,430
28,269
29,149
41,838
81,409
42,420
127,316
58,043
57,263
57,533
57,53357,26358,043127,31642,42081,40941,83829,14928,26927,43025,4069,43517,5248,09317,62016,93016,3867,93515,34414,83214,3386,82313,17412,71410,5561,7141,9912,4062,8203,2323,5323,6932,7183,1293,3704,1894,4283,8444,1343,7082,1271,7040000
       Short Long Term Debt 
0
0
0
0
1,704
0
0
0
3,266
0
3,611
3,370
2,551
2,718
2,671
1,818
1,518
1,106
692
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,290
16,851
17,382
17,857
30,221
30,278
30,180
48,259
45,032
43,917
43,797
43,79743,91745,03248,25930,18030,27830,22117,85717,38216,85115,29000000000000000006921,1061,5181,8182,6712,7182,5513,3703,61103,2660001,7040000
       Accounts payable 
1,414
0
0
0
814
2,334
1,611
1,562
2,455
2,773
2,730
1,848
2,211
2,282
2,581
2,092
3,744
3,288
2,980
3,988
3,298
4,421
6,608
2,203
4,793
8,468
5,591
2,929
4,370
2,889
1,847
9,549
8,333
17,961
15,053
4,233
2,729
10,563
6,979
6,963
4,710
4,926
4,858
4,716
6,790
800
8006,7904,7164,8584,9264,7106,9636,97910,5632,7294,23315,05317,9618,3339,5491,8472,8894,3702,9295,5918,4684,7932,2036,6084,4213,2983,9882,9803,2883,7442,0922,5812,2822,2111,8482,7302,7732,4551,5621,6112,3348140001,414
       Other Current Liabilities 
1,031
0
0
0
4,246
4,794
3,809
7,256
6,443
4,762
7,032
7,410
11,746
10,363
17,422
23,797
30,541
29,087
39,808
45,181
53,425
45,548
57,769
73,832
88,706
66,792
84,663
81,444
118,497
78,286
98,708
85,730
133,339
91,936
119,282
120,763
-295,546
-309,481
-312,769
148,583
127,992
159,257
107,881
130,881
133,088
189,972
189,972133,088130,881107,881159,257127,992148,583-312,769-309,481-295,546120,763119,28291,936133,33985,73098,70878,286118,49781,44484,66366,79288,70673,83257,76945,54853,42545,18139,80829,08730,54123,79717,42210,36311,7467,4107,0324,7626,4437,2563,8094,7944,2460001,031
   > Long-term Liabilities 
0
0
0
0
7,732
16,557
20,168
17,855
16,279
52,569
46,204
45,759
41,205
38,667
37,640
43,388
48,877
53,597
61,848
60,535
60,792
135,687
132,845
127,439
136,853
132,404
131,004
128,070
117,503
112,929
114,594
110,544
131,725
124,616
285,936
642,575
651,991
633,388
626,287
705,304
703,718
521,185
639,516
628,840
620,352
602,889
602,889620,352628,840639,516521,185703,718705,304626,287633,388651,991642,575285,936124,616131,725110,544114,594112,929117,503128,070131,004132,404136,853127,439132,845135,68760,79260,53561,84853,59748,87743,38837,64038,66741,20545,75946,20452,56916,27917,85520,16816,5577,7320000
       Long term Debt Total 
0
0
0
0
0
6,525
5,710
4,893
4,072
3,246
2,672
2,095
1,518
1,106
692
277
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
165,742
526,234
535,277
535,346
531,077
0
0
0
0
0
0
0
0000000531,077535,346535,277526,234165,7420000000000000000002776921,1061,5182,0952,6723,2464,0724,8935,7106,52500000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-1,704
-2,127
-3,708
-4,134
-3,844
-4,428
-4,189
-3,370
-3,129
-2,718
-3,693
-3,532
-3,232
-2,820
-2,406
-1,991
-1,714
89,044
86,289
84,334
89,126
80,498
78,311
76,063
81,669
71,284
68,807
66,244
103,315
92,000
98,160
80,205
75,938
72,558
69,192
53,815
12,275
48,309
-39,414
26,884
24,873
21,419
21,41924,87326,884-39,41448,30912,27553,81569,19272,55875,93880,20598,16092,000103,31566,24468,80771,28481,66976,06378,31180,49889,12684,33486,28989,044-1,714-1,991-2,406-2,820-3,232-3,532-3,693-2,718-3,129-3,370-4,189-4,428-3,844-4,134-3,708-2,127-1,7040000
       Warrants
0
0
0
0
0
403
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000040300000
       Long-term Liabilities Other 
0
0
0
0
0
147
3,843
3,734
3,622
3,507
3,389
3,148
2,946
2,813
3,180
8,542
14,748
14,277
14,044
55,629
55,662
135,687
132,845
127,439
136,853
132,404
131,004
128,070
117,503
7,355
6,957
6,885
131,725
124,616
120,194
116,341
116,714
98,042
95,210
3,101
6,213
5,766
5,784
6,167
6,792
6,972
6,9726,7926,1675,7845,7666,2133,10195,21098,042116,714116,341120,194124,616131,7256,8856,9577,355117,503128,070131,004132,404136,853127,439132,845135,68755,66255,62914,04414,27714,7488,5423,1802,8132,9463,1483,3893,5073,6223,7343,84314700000
       Deferred Long Term Liability 
0
0
0
0
99
9,482
10,514
8,523
8,585
45,816
40,143
40,516
36,741
34,748
33,768
34,569
34,129
4,389
4,648
4,906
5,130
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000005,1304,9064,6484,38934,12934,56933,76834,74836,74140,51640,14345,8168,5858,52310,5149,482990000
> Total Stockholder Equity
0
-1,377
0
0
35,429
24,723
169,589
158,142
143,979
129,659
112,562
97,710
213,078
188,222
374,089
341,240
623,970
570,873
552,932
489,296
419,009
344,213
592,827
516,344
464,359
682,931
581,367
1,320,000
1,470,088
1,400,021
1,328,804
1,247,087
970,735
881,666
747,750
640,307
514,677
414,298
311,130
202,611
130,609
310,687
320,241
313,148
298,665
342,131
342,131298,665313,148320,241310,687130,609202,611311,130414,298514,677640,307747,750881,666970,7351,247,0871,328,8041,400,0211,470,0881,320,000581,367682,931464,359516,344592,827344,213419,009489,296552,932570,873623,970341,240374,089188,222213,07897,710112,562129,659143,979158,142169,58924,72335,42900-1,3770
   Retained Earnings -2,406,535-2,407,031-2,357,076-2,300,800-2,250,806-2,339,942-2,229,025-2,095,311-1,962,518-1,832,958-1,674,312-1,541,149-1,381,440-1,275,441-956,755-839,514-731,070-631,356-545,688-1,179,666-1,056,194-945,238-878,908-784,633-684,952-597,545-517,223-444,501-417,452-355,589-306,562-268,859-235,447-207,470-186,206-169,373-150,479-134,975-119,400-106,758-93,778-82,2060000
   Accumulated Other Comprehensive Income 
0
-41,454
0
0
-1,546
0
-204,208
-195,288
-2,077
31
55
27
-18
-114
-314
-165
-269
-591
-381
-337
-180
75
927
637
-2,535
-69
-1,120
-1,940
-5,214
-5,097
-5,835
-5,673
-4,133
-12,110
-14,248
-14,826
-10,443
-4,602
-4,221
-2,683
-3,495
-3,847
-3,890
-1,070
-3,551
-3,237
-3,237-3,551-1,070-3,890-3,847-3,495-2,683-4,221-4,602-10,443-14,826-14,248-12,110-4,133-5,673-5,835-5,097-5,214-1,940-1,120-69-2,53563792775-180-337-381-591-269-165-314-114-18275531-2,077-195,288-204,2080-1,54600-41,4540
   Capital Surplus 
0
0
0
0
0
3,691
276,320
277,515
278,927
280,080
281,853
283,862
420,533
423,750
643,223
647,928
979,785
988,872
997,770
1,006,812
1,016,690
1,029,046
1,376,484
1,394,566
1,412,083
1,739,140
1,762,099
1,867,572
2,106,600
2,136,130
2,174,094
2,209,456
2,250,250
2,275,156
2,303,087
2,329,385
2,358,018
2,381,358
2,410,601
0
0
0
0
0
0
0
00000002,410,6012,381,3582,358,0182,329,3852,303,0872,275,1562,250,2502,209,4562,174,0942,136,1302,106,6001,867,5721,762,0991,739,1401,412,0831,394,5661,376,4841,029,0461,016,6901,006,812997,770988,872979,785647,928643,223423,750420,533283,862281,853280,080278,927277,515276,3203,69100000
   Treasury Stock0000000000000000000000000000000000000000000000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue508,824
Cost of Revenue-20,163
Gross Profit488,661488,661
 
Operating Income (+$)
Gross Profit488,661
Operating Expense-700,705
Operating Income-212,044-212,044
 
Operating Expense (+$)
Research Development341,433
Selling General Administrative262,668
Selling And Marketing Expenses96,604
Operating Expense700,705700,705
 
Net Interest Income (+$)
Interest Income40,655
Interest Expense-68,806
Other Finance Cost-0
Net Interest Income-28,151
 
Pretax Income (+$)
Operating Income-212,044
Net Interest Income-28,151
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-65,863-358,225
EBIT - interestExpense = -65,863
-65,863
1,717
Interest Expense68,806
Earnings Before Interest and Taxes (EBIT)2,9432,943
Earnings Before Interest and Taxes (EBITDA)19,234
 
After tax Income (+$)
Income Before Tax-65,863
Tax Provision-1,226
Net Income From Continuing Ops-67,089-67,089
Net Income-67,089
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses720,868
Total Other Income/Expenses Net146,18128,151
 

Technical Analysis of Blueprint Medicines Corp
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Blueprint Medicines Corp. The general trend of Blueprint Medicines Corp is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Blueprint Medicines Corp's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Blueprint Medicines Corp Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Blueprint Medicines Corp.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 128.45.

The bearish price targets are: 121.90 > 118.25 > 104.86.

Know someone who trades $BPMC? Share this with them.👇

Blueprint Medicines Corp Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Blueprint Medicines Corp. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Blueprint Medicines Corp Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Blueprint Medicines Corp. The current macd is 4.65018298.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Blueprint Medicines Corp price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Blueprint Medicines Corp. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Blueprint Medicines Corp price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Blueprint Medicines Corp Daily Moving Average Convergence/Divergence (MACD) ChartBlueprint Medicines Corp Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Blueprint Medicines Corp. The current adx is 47.58.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Blueprint Medicines Corp shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Blueprint Medicines Corp Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Blueprint Medicines Corp. The current sar is 125.10.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Blueprint Medicines Corp Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Blueprint Medicines Corp. The current rsi is 74.59. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Blueprint Medicines Corp Daily Relative Strength Index (RSI) ChartBlueprint Medicines Corp Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Blueprint Medicines Corp. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Blueprint Medicines Corp price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Blueprint Medicines Corp Daily Stochastic Oscillator ChartBlueprint Medicines Corp Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Blueprint Medicines Corp. The current cci is 104.68.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Blueprint Medicines Corp Daily Commodity Channel Index (CCI) ChartBlueprint Medicines Corp Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Blueprint Medicines Corp. The current cmo is 51.67.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Blueprint Medicines Corp Daily Chande Momentum Oscillator (CMO) ChartBlueprint Medicines Corp Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Blueprint Medicines Corp. The current willr is -25.56390977.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Blueprint Medicines Corp is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Blueprint Medicines Corp Daily Williams %R ChartBlueprint Medicines Corp Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Blueprint Medicines Corp.

Blueprint Medicines Corp Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Blueprint Medicines Corp. The current atr is 1.34491774.

Blueprint Medicines Corp Daily Average True Range (ATR) ChartBlueprint Medicines Corp Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Blueprint Medicines Corp. The current obv is 35,803,058.

Blueprint Medicines Corp Daily On-Balance Volume (OBV) ChartBlueprint Medicines Corp Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Blueprint Medicines Corp. The current mfi is 50.88.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Blueprint Medicines Corp Daily Money Flow Index (MFI) ChartBlueprint Medicines Corp Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Blueprint Medicines Corp.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-20MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-04-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-02ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-03MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside

6.3. Candlestick Patterns

Blueprint Medicines Corp Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Blueprint Medicines Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5074.588
Ma 20Greater thanMa 50128.143
Ma 50Greater thanMa 100111.575
Ma 100Greater thanMa 200100.425
OpenGreater thanClose128.250
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Blueprint Medicines Corp with someone you think should read this too:
  • Are you bullish or bearish on Blueprint Medicines Corp? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Blueprint Medicines Corp? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Blueprint Medicines Corp

I send you an email if I find something interesting about Blueprint Medicines Corp.


Comments

How you think about this?

Leave a comment

Stay informed about Blueprint Medicines Corp.

Receive notifications about Blueprint Medicines Corp in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.